Analysis links DPP-4 inhibitors to reduced CVD risk in diabetes

09/25/2011 | InternalMedicineNews.com (free registration)

A meta-analysis presented at the European Association for the Study of Diabetes showed that type 2 diabetes patients who took dipeptidyl peptidase–4 inhibitors had a 31% decreased risk of major cardiovascular events, compared with those taking a placebo or other treatments. However, the review has limitations, including that cardiovascular events were not the end point in any of the studies, and further investigation is needed, the lead researcher said.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA